Skip to main content
Retour
ZYME logo

Zymeworks Inc.

Qualité des données : 100%
ZYME
NASDAQ Healthcare Biotechnology
24,02 €
▲ 0,70 € (3,00%)
Cap. Boursière : 1,78B
Fourchette du Jour
23,70 € 24,19 €
Fourchette 52 Semaines
9,03 € 28,49 €
Volume
522 742
Moyenne 50J / 200J
23,44 € / 19,06 €
Clôture Précédente
23,32 €

Historique des Prix

Tendances Financières

Comparaison Sectorielle

vs médiane du secteur Healthcare (626 pairs)

Métrique Action Médiane du Secteur
P/E -22,0 0,4
P/B 6,7 2,9
ROE % -26,7 3,7
Net Margin % -76,6 3,8
Rev Growth 5Y % 41,2 10,0
D/E 0,1 0,2

Points Clés

Revenue grew 41,17% annually over 5 years — strong growth
Debt/Equity of 0,07 — conservative balance sheet
Negative free cash flow of -34,53M
PEG of 0,73 suggests growth is underpriced
Capital efficient — spends only 1,44% of revenue on capex

Croissance

Revenue Growth (5Y)
41,17%
Revenue (1Y)38,87%
Earnings (1Y)N/A
FCF Growth (3Y)N/A

Qualité

Return on Equity
-26,72%
ROIC-24,20%
Net Margin-76,56%
Op. Margin-87,34%

Sécurité

Debt / Equity
0,07
Current Ratio5,52
Interest Coverage0,00

Valorisation

P/E Ratio
-22,00
P/B Ratio6,65
EV/EBITDAN/A
Dividend Yield0,00%

All Fundamental Metrics

Growth
Revenue Growth (1Y) 38,87% Revenue Growth (3Y) 18,07%
Earnings Growth (1Y) N/A Earnings Growth (3Y) N/A
Revenue Growth (5Y) 41,17% Earnings Growth (5Y) N/A
Profitability
Revenue (TTM) 105,97M Net Income (TTM) -81,13M
ROE -26,72% ROA -23,41%
Gross Margin 89,81% Operating Margin -87,34%
Net Margin -76,56% Free Cash Flow (TTM) -34,53M
ROIC -24,20% FCF Growth (3Y) N/A
Safety
Debt / Equity 0,07 Current Ratio 5,52
Interest Coverage 0,00 Dividend Yield 0,00%
Valuation
P/E Ratio -22,00 P/B Ratio 6,65
P/S Ratio 16,84 PEG Ratio 0,73
EV/EBITDA N/A Dividend Yield 0,00%
Market Cap 1,78B Enterprise Value 1,76B

Income Statement

Annual, most recent first

Income statement data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Revenue 105,97M 76,30M 76,01M 412,48M 26,68M
Net Income -81,13M -122,70M -118,67M 124,34M -211,84M
EPS (Diluted) -1,08 -1,62 -1,72 1,90 -4,61
Gross Profit 95,17M 76,30M -66,98M 412,48M 26,68M
Operating Income -92,55M -137,11M -138,05M 130,53M -215,63M

Balance Sheet

Annual, most recent first

Balance sheet data, annual, most recent first
Metric FY2025 FY2024 FY2023 FY2022 FY2021
Total Assets 346,53M 463,09M 580,88M 648,73M 389,13M
Total Liabilities 78,03M 124,32M 116,07M 155,77M 140,04M
Shareholders' Equity 268,50M 338,77M 464,81M 492,96M 249,09M
Total Debt 18,27M 18,51M 26,72M 28,11M 32,33M
Cash & Equivalents 41,16M 66,10M 157,56M 400,91M 201,87M
Current Assets 233,44M 300,45M 412,93M 544,71M 288,22M
Current Liabilities 42,32M 88,29M 55,76M 95,63M 71,85M

Scores de Stratégies

This stock passed the criteria for 1 strategy

Score = fit strength (0–100)
Rank = position among all matches
Custom Full Throttle
#47 of 146
54

Activité Récente

Entré Full Throttle
Mar 24, 2026